Plain-English translation of NCT07133958 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is tracking how tumors shrink and respond when patients with advanced oral or throat cancer receive a combination of chemotherapy and immunotherapy before surgery. The study will review records from patients treated in 2023 and also follow new patients as they go through this treatment. The goal is to understand the different patterns of how these tumors respond to this medication so doctors can better predict outcomes and plan surgery.
Doctors want to better understand how tumors behave and shrink when treated with this combination therapy before surgery. By studying these patterns, they hope to improve how they plan surgery and predict which patients will benefit most from this treatment approach.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will either have your medical records reviewed if you were treated in 2023, or you will be followed prospectively as you receive the chemotherapy and immunotherapy treatment before your planned surgery. The researchers will track how your tumor responds to the medication, monitor your health, and collect information about your treatment outcomes and recovery.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
China
Sponsor
Zhujiang Hospital
Enrollment target
~35 participants
Started
July 2023
Primary completion
March 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiaozhi LV
Zhujiang Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.